Noxon
Berlin, Germany· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A German biotech developing RNA-based medicines for rare genetic diseases.
Rare DiseaseGenetics & Genomics
Technology Platform
A proprietary RNA therapeutics platform focusing on advanced antisense oligonucleotide (ASO) chemistry and design for precise genetic modulation.
Opportunities
Potential to deliver transformative, one-time treatments for devastating rare diseases with high unmet need and favorable regulatory pathways.
Risk Factors
Clinical development risks in small patient populations and potential for off-target effects or safety issues with novel RNA chemistries.
Competitive Landscape
Competes with established RNA therapy leaders and other niche rare disease biotechs, requiring clear differentiation in delivery or target selection.